Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Marker Therapeutics Inc MRKR

Healthcare Biotechnology

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered... see more

Add To Watchlist

Recent & Breaking News (NDAQ:MRKR)

TapImmune Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients

PR Newswire June 23, 2015

TapImmune Announces Immediate Infusion of $2.5 Million Dollars From Largest Institutional Investor

PR Newswire June 18, 2015

Three Companies with the Ingredients to Follow in the Footsteps of Advaxis (NASDAQ: ADXS)

Accesswire June 16, 2015

TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation

PR Newswire June 2, 2015

TapImmune to Present Clinical & Scientific Update at the 2015 Marcum Microcap Conference

PR Newswire May 20, 2015

Quiet Biotech Gains Traction After Cancer Vaccine Draws National Media Coverage Ahead of Upcoming ASCO Meeting

Accesswire May 20, 2015

Phase I Study in Ovarian & Breast Cancer Published in Abstracts of 2015 ASCO Annual Meeting

PR Newswire May 15, 2015

Presentation at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality"

PR Newswire March 30, 2015

TapImmune to Present at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" on Thursday March 26, 2015

PR Newswire March 25, 2015

TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors

PR Newswire March 19, 2015

TapImmune Receives $1,000,000 from Strategic Investor

PR Newswire March 10, 2015

TapImmune Appoints John Bonfiglio as Strategic Advisor

PR Newswire February 25, 2015

TapImmune Appoints Patrick D. Yeramian, MD, Consulting Medical Director to Lead Phase II Clinical Trials in Triple Negative Breast and HER2/neu Breast Cancer

PR Newswire February 23, 2015

TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015

PR Newswire February 20, 2015

TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations

PR Newswire February 19, 2015

TapImmune's CEO Says Company Is Preparing "A Very Deep Pipeline in Multiple Indications" for Phase II Trials

Marketwired February 10, 2015

Positive Phase 1 Immune Responses in All Evaluable Ovarian and Breast Cancer Patients Advances Vaccine to Phase II Clinical Trials

PR Newswire January 12, 2015

TapImmune, Inc. Announces $1,464,000 Million Registered Direct Offering

PR Newswire January 12, 2015

TapImmune CEO Discusses Company's Clinical Programs in Recent Print and Radio Interviews

PR Newswire November 24, 2014

TapImmune Announces Phase II Clinical Trials Collaboration With VGTI Florida to Advance Breast and Ovarian Cancer Vaccines

PR Newswire November 18, 2014